Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response.

Katia BeiderEvgenia RosenbergValeria Dimenshtein-VoevodaYaarit SirovskyJulia VladimirskyHila MagenOlga OstrovskyAvichai ShimoniZohar BrombergLola WeissAmnon PeledArnon Nagler

Published in: Journal of hematology & oncology (2020)

Altogether, our results unravel the mechanism mediating the strong synergistic anti-MM activity of bortezomib in combination with TRPV1 inhibition which may be translated into the clinic.

Keyphrases

multiple myeloma
cancer therapy
neuropathic pain
high glucose
diabetic rats
primary care
binding protein
endoplasmic reticulum stress
small molecule
drug induced
amino acid
spinal cord injury
nlrp inflammasome
spinal cord
climate change